We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hemogenyx Pharmaceuticals Plc | LSE:HEMO | London | Ordinary Share | GB00BYX3WZ24 | ORD GBP0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.015 | -0.99% | 1.50 | 1.45 | 1.55 | 1.50 | 1.50 | 1.50 | 878,343 | 10:29:49 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -3.98M | -0.0035 | -4.31 | 17.24M |
Date | Subject | Author | Discuss |
---|---|---|---|
14/3/2020 16:03 | Re Post 1329 I Googled : "Neutralizing antibodies against emerging pathogens are going mainstream, Hemogenyx" And the following article appeared on the first page, noting that the search indicated that the words "Neutralizing" and "Mainstream" were excluded. Proactive Hemogenyx develops new mouse model which could play a big role in future wars 08:26 Mon 24 Jun 2019 Hemogenyx thinks its new ApbHC mouse model could be used to rapidly develop antibodies to treat deadly pathogens such as Anthrax released as an act of war HemoGenyx Pharmaceuticals PLC (LON:HEMO) has developed a new generation of humanised mice which it believes could play a vital role in protecting people caught up in biological warfare. Governments spend billions of dollars every year protecting their citizens from the threat of biological weapons, such as the release of pathogens and toxins including anthrax and smallpox. Hemogenyx thinks its new mouse model, called Advanced peripheral blood Hematopoietic Chimera (ApbHC), could potentially be used to help rapidly develop treatments against unknown human-specific pathogens. ApbHC has “several advantages” over other mouse models, says Hemogenyx, including the absence of Graft versus Host disease – when the mouse rejects the transplanted tissue – which makes the use of certain cells impossible. Article continues....... | tullynessle | |
14/3/2020 15:31 | Purple Post 1327 1328 prepared concurrently with your 1327. I agree with your thoughts that Lilly may be the global co partner? I suppose there has to be some reasons for Hemogenyx to highlight the News Release, although it many be as simple as general interest in medical/research process, progress in managing the pandemic, or reference to "Neutralizing antibodies against emerging pathogens are going mainstream." | tullynessle | |
14/3/2020 15:25 | Hemogenyx highlighted the Lilly News Release in its tweet, however not sure which component of the research / discovery process is similar to Hemogenyx technology, (if any). I noticed that the document mentions that "our goal with AbCellera is to be testing potential new therapies in patients within the next four months." so that appears to be good news. 03/12/2020 AbCellera and Lilly will select from 500+ unique antibodies isolated from one of the first U.S. patients who recovered from COVID-19 to create antibody therapeutics for treatment and prevention of COVID- VANCOUVER, British Columbia and INDIANAPOLIS, March 12, 2020 /PRNewswire/ -- AbCellera and Eli Lilly and Company (NYSE: LLY) announced today they have entered into an agreement to co-develop antibody products for the treatment and prevention of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus. The collaboration will leverage AbCellera's rapid pandemic response platform, developed under the DARPA Pandemic Prevention Platform (P3) Program, and Lilly's global capabilities for rapid development, manufacturing and distribution of therapeutic antibodies. Within one week of receiving a blood sample from one of the first U.S. patients who recovered from COVID-19, AbCellera screened over 5 million immune cells looking for ones that produced functional antibodies that helped the patient neutralize the virus and recover from the disease. From this effort, AbCellera has identified over 500 unique fully human antibody sequences, the largest panel of anti-SARS-CoV-2 antibodies ever reported. The next step is to screen these antibodies to find the ones most effective in neutralizing SARS-CoV-2. Many of these antibodies will be expressed in collaboration with partners at the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and pending agreement with NIAID will be tested for their ability to neutralize the virus. "AbCellera's platform has delivered, with unprecedented speed, by far the world's largest panel of anti-SAR-CoV-2 antibodies," said Carl Hansen, Ph.D., CEO of AbCellera. "In 11 days, we've discovered hundreds of antibodies against the SARS-CoV-2 virus responsible for the current outbreak, moved into functional testing with global experts in virology, and signed a co-development agreement with one of the world's leading biopharmaceutical companies. We're deeply impressed with the speed and agility of Lilly's response to this global challenge. Together, our teams are committed to delivering a countermeasure to stop the outbreak." "With the number of cases rapidly increasing all over the world, doctors and patients are seeking a therapeutic intervention that can speed their recovery or prevent the disease. Lilly is committed to playing our part to bring innovation to patients amidst this global outbreak," said Daniel Skovronsky, M.D., Ph.D., Lilly's chief scientific officer and president of Lilly Research Laboratories. "We've partnered with AbCellera because we're impressed with the speed and quality of their efforts. We are moving at top speed to create a potential treatment to help patients. While typically a new therapeutic antibody program might take years to get in the clinic, our goal with AbCellera is to be testing potential new therapies in patients within the next four months." Under the terms of the agreement, AbCellera and Lilly have committed to equally share initial development costs towards a product, after which Lilly will be responsible for all further development, manufacturing and distribution. If successful, Lilly is ready to work with global regulators to bring a treatment to patients. ==================== Hemogenyx @HemoGenyx · 4h Neutralizing antibodies against emerging pathogens are going mainstream. | tullynessle | |
14/3/2020 15:09 | hemogenyx tweeting about lilly.is this the global co partner? Hemogenyx @HemoGenyx Neutralizing antibodies against emerging pathogens are going mainstream. AbCellera and Lilly to Co-develop Antibody Therapies for the Treatment of COVID-19 | Eli Lilly and... The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts. investor.lilly.com | purple11 | |
14/3/2020 11:56 | Seems to have nothing to do with Hemogenyx...!! I have written to the Dr , but so far he has failed to respond to my many questions | johntopdog | |
13/3/2020 13:46 | Agree i don't think it's a good time for Hemo to be agreeing a deal and probably not for a pharma company either. Big pharma who source most raw materials from China must be hurting. Hemo have a years cash, they should get on with background works and given Dr Vlad and Sir Feldmanns ages I hope they put their own health first in these worrying times. Work from home, can't cure anyone if they fall badly ill. Look after yourselves board members, long and short. We're mostly human. PS I've saved myself £270k in the past 2 months, stick that up your imaginary trading apps pipe. So long | quickdraw18 | |
12/3/2020 16:23 | I doubt we'll be getting an rns until the market settles down.it would just be lost in this carnage. | purple11 | |
12/3/2020 16:18 | im not putting anymore in here.i have what I have. But for new investors could be a fantastic entry. | purple11 | |
12/3/2020 16:14 | It's a great time to have a load of spare cash to invest. Pity I don't have any. | on target | |
12/3/2020 16:11 | when will this end/its just another seasonal flu.absolutely bonkers. | purple11 | |
12/3/2020 16:06 | ftse down 10.8%!! | purple11 | |
12/3/2020 15:48 | Can buy 2m online at the moment if dummy quotes are to be believed. Not sure what would happen if I had the cash and pressed the button though. | on target | |
12/3/2020 15:31 | should start attracting some buying now once the market settles...….. | purple11 | |
12/3/2020 15:29 | 5.8m cap now | purple11 | |
12/3/2020 14:00 | Marie, stop writing stuff like you knew what this company is about. The only reason you say it's a scam is because what I've told you. You were yet another clueless investor, you even copied word for word my questions to the company. You didn't find out it's a scam, I did. You're still licking your wounds at a loss, or you gonna tell us you're shorting it now 😂 | davevt | |
12/3/2020 11:05 | Okay members, Time to say goodbye. Left so many footprints here but brace for another ID soon. I want to enjoy my winning for few days. Bye bye to Dartford boys. I used to Andy them but they both dumped me: Right, you won’t hear from me from this id: Bye bye | make_some_noise_4_dartford_boys | |
12/3/2020 11:00 | stick to Bingo. better odds | purple11 | |
12/3/2020 09:57 | Purple see SNG NOW ONWARD I WILL CHARGE YOU FOR MY TIP I’m not idiot like DAVE | make_some_noise_4_dartford_boys | |
12/3/2020 09:52 | Cull purple cull Everyone idiot should deserve to lose 90% here and in broader market 2008 didn’t give any lesson to anyone Spartaaaaaa | make_some_noise_4_dartford_boys | |
12/3/2020 09:40 | Patience needed. Kept hearing this. It’s not a rocket science to understand that this is scam. Don’t believe me: Scan all their RNS again. 2 years is not a small time: Remember no IND news And wtf is that “globalco̶ You just couldn’t make it up lol | make_some_noise_4_dartford_boys | |
12/3/2020 09:28 | Purple; I’m waiting for your legendary sentence What a useless thread this is Same like HEMO: what a scam company this is haha I’m surprised Dr. Didn’t put RNS of corona virus I would have died in that case lol You just couldn’t make it up hahaha SPARTAAAAAAA | make_some_noise_4_dartford_boys |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions